Toripalimab + Chemotherapy

Phase 2

Coherus Oncology, Inc. (CHRS)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Head and Neck Cancer

GRTXDrug: GC4419

Phase 2

View Full Landscape

Drug Information

Target Indication

Head and Neck Cancer

Clinical Trial

NCT07209189

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/19/2024

Loqtorzi

Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

CHRS

Coherus Oncology, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

CHS-1420Phase 3

Plaque Psoriasis

CHS-0214Phase 3

Plaque Psoriasis